Serine proteases play a key role in the fundamental biology of the central nervous system (CNS), and recent data suggest their involvement in the pathophysiology of neurodegenerative diseases. Little is known about the physiological regulation of these proteases in the CNS. Among the multiple growth factors present in the brain, transforming growth factor b1 (TGF-b1) has been described as an injury-related growth factor. However, its beneficial or deleterious role remains unclear. In the present study, we investigated the influence of TGF-b1 in apoptosis and necrosis, two mechanisms involved in ischemic neuronal death. We show that TGF-b1 exerts a neuroprotective role restricted to necrosis induced by N-methyl-D-aspartate. This effect is observable only in the obligatory presence of TGF-b1-responsive astrocytes. We demonstrate that this neuroprotective activity is mediated through an up-regulation of a serine protease inhibitor (PAI-1) in astrocytes. These results underline the involvement of serine proteases and extracellular matrix components such as the PAI-1/t-PA axis in the excitotoxic cascade. Moreover, regardless of the underlying mechanisms of t-PA involvement in excitotoxic injury, our observations might warn against the use of tissular plasminogen activator as an alternative therapy for the treatment of hypoxic-ischemic injury in the brain.-Buisson, A., Nicole, O., Docagne, F., Sartelet, H., MacKenzie, E. T., Vivien, D. Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor b1. FASEB J. 12, 1683-1691 (1998) 
TRANSFORMING GROWTH FACTORS bs (TGF-bs) 3 are abundantly expressed in the central nervous system and are involved in many biological processes ranging from the inhibition of cell proliferation to determination of cell fate during embryogenesis (1) . By acting through a set of high-affinity serine-threonine kinase receptors (2) (TbR-II and TbR-I), TGF-b1 promotes the inhibition of the cell cycle and modulates the composition of the extracellular matrix (3) . TbR-II binds TGF-b1 on its own and recruits TbR-I to signal through the activation of Smad 2/3 (Sma and Mad-related protein) and Smad 4 transcriptional factors (2) .
Several growth factors attenuate neuronal death when induced by a large variety of insults. For example, many growth factors can inhibit several forms of axotomy-induced death, an apoptotic death that most likely reflects a failure of target-supplied trophic factors to reach the cell body. It is now recognized that apoptosis, characterized by a decrease in cell volume, membrane blebbing, chromatin condensation, and DNA fragmentation (4) , is implicated in the pathogenesis of many neurodegenerative diseases (5) . Accordingly, the concept has emerged that the survival-promoting properties of growth factors are crucial in the determination of apoptotic injury. Consistent with these data, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 all attenuate apoptosis in neurons (6) . In contrast, when applied to cerebellar neurons, TGF-b1 does not seem to exert a neurotrophic effect, but rather surprisingly induces apoptosis in neurons (7) . As several studies have described elevated concentrations of TGF-b1 in brain biopsies from patients with Parkinson's (8) or Alzheimer's (9) 
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stroke (10) , this growth factor has been characterized as an injury-related peptide. However, the beneficial or deleterious effect of the increased concentration of TGF-b1 in altered brain tissue remains controversial (11, 12) . TGF-b1 activates the transcription of genes important in the progression of the cell cycle, such as cyclin dependent kinase inhibitors, (13) as well as some involved in the maintenance of the extracellular matrix such as a2(1) procollagen, fibronectin, and plasminogen activator inhibitor type 1 (PAI-1) (14, 15) . The extracellular matrix degradation-regulation effect of the TGF-b isoforms has been described in many systems and seems to be mediated primarily by an overexpression of PAI-1 (15, 16) . PAI-1 is an inhibitory peptide for tissue-type plasminogen activator (t-PA), a serine protease that converts inactive plasminogen to active protease plasmin (16) . The activity of t-PA has been studied extensively in neural tissue and seems to be implicated not only in neurite outgrowth, cell migration (17) , and synaptic plasticity (18) but also in the excitotoxic cascade after focal cerebral ischemia (19) . Based on the above results, we postulate that the neuroprotective effect of TGF-b1 may involve the modulation of t-PA activity through an increased PAI-1 synthesis in astrocytes.
MATERIALS AND METHODS
Polymerase chain reaction kit was purchased from Life Technologies (Cergy Pontoise, France) and a reverse transcriptase system kit was obtained from Promega (Paris, France). Protein G Sepharose was from Pharmacia Biotech (Uppsala, Sweden). Luciferase assay kit was purchased from Promega, Lipofectamine was obtained from Life Technologies and SV40-b-galactosidase reporter vector was from Promega. Human recombinant TGF-b1 was purchased from R&D (Oxon, U.K.).
35
S-Methionine, 35 S-cysteine, and 3 H-thymidine were obtained from NEN (Les Ulis, France). N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), kainate, and (/)5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine maleate (MK-801) were from Tocris (Bristol, U.K.). Staurosporine and cycloheximide were purchased from Sigma Chemical Co. (Isle D'Abeau, France). Eagle's minimal essential medium (MEM), cytosine arabinoside, horse serum, and fetal bovine serum were obtained from Sigma; poly-D-lysine and laminin were from Life Technologies. Anti-MAP-2 and anti-GFAP antibodies were purchased from Sigma; anti-PAI-1 and anti-t-PA antibodies were from American Diagnostica (Greenwich, Conn.). All other chemicals used were obtained from Sigma.
Cell culture
Mixed cortical cultures containing both neuronal and glial cells were prepared from fetal mice at 15-16 days gestation (20) . Cerebral cortices were dissected and incubated for 20-30 min in 0.025% trypsin in media stock (MS, Eagle's minimal essential medium augmented with 2 mM glutamine and 25 mM glucose) and transferred to MS supplemented with 5% fetal bovine and 5% horse serum for trituration. Dissociated cells were plated at a density of about 3 1 10 5 cells per well on an established bed of glia in MS supplemented with 10% fetal bovine serum and 10% horse serum. Cortical astrocyte cell cultures were prepared similarly from 1-to 3-day-old postnatal pups, using plating medium supplemented with epidermal growth factor (10 ng/ml) (20) .
All cultures were kept at 37ЊC in a humidified 5% CO 2 -containing atmosphere. After 3-7 days in vitro, glial cell division was halted by exposure to 10 mM cytosine arabinoside. Cells were subsequently shifted into maintenance medium, which was identical to the plating medium but lacking fetal bovine serum. The medium was changed twice weekly. Experiments were performed on cortical cultures after 14-15 days in vitro.
Near-pure neuronal cell cultures containing less than 5% astrocytes were prepared as previously detailed (21) . Dissociated cortical cells in MS supplemented with 5% fetal bovine and 5% horse serum were plated in multiwell vessels that had previously been coated with poly-D-lysine and laminin, using conditioned medium from astrocyte cultures with 3 mM cytosine arabinoside. There was no further exchange of the media. Experiments were performed on neuronal cultures after 14-15 days in vitro.
Apoptosis
Serum deprivation (SD) was initiated by transferring pure neuronal cultures (DIV 7) into growth medium lacking serum. Neuronal cell death was assessed by cell counts after staining with 0.4% trypan blue dye.
Staurosporine (STP) exposure was induced at 37ЊC in mixed cortical cell culture (DIV 14) by a 24 h exposure to 200 nM of STP in MS supplemented with glycine. MK-801 (10 mM) was always added concurrently with STP to block secondary NMDA receptor activation.
Excitotoxicity
Slowly triggered excitotoxicity was induced at 37ЊC by a 24 h exposure to 15 mM NMDA, 10 mM AMPA, or 35 mM kainate in MS supplemented with glycine. MK-801 (10 mM) was always added concurrently with AMPA or kainate to block secondary NMDA receptor activation. TGF-b1 was coapplied with the excitotoxin and left in the bathing media for 24 h.
Assessment of neuronal cell death
Neuronal death was estimated by examination of the cultures under phase-contrast microscopy, and quantitated by measurement of lactate dehydrogenase (LDH) release by damaged cells into the bathing medium 1 day after the onset of excitotoxic exposure (22) . The LDH level corresponding to near-complete neuronal death (without glial death) was determined in sister cultures exposed to 200 mM NMDA for 24 h in MS supplemented with glycine. Background LDH levels were determined in sister cultures subjected to sham wash and subtracted from experimental values to yield the signal specific to experimentally induced injury.
Reverse transcription and polymerase chain reaction
Total RNAs were transcribed into cDNA using poly-dT oligonucleotides. An aliquot of the cDNAs so produced was amplified using sense and antisense primers for b-actin [539 bp polymerase chain reaction (PCR) product], PAI-1 (331 bp PCR product), and t-PA (252 bp PCR product), respectively (30 cycles of PCR were chosen corresponding to 50% of the saturating curve of the PCR products). b-Actin sense oligonucleotide: GTG GGC CGC TCT AGG CAC AA, and antisense oligonucleotide: CTC TTT GAT GTC ACGCAC GAT TTC; / 383c de08 Mp 1685 Tuesday Oct 20 11:08 PM LP-FASEB de08 PAI-1 sense oligonucleotide: ATG AGA TCA GTA CTG CGG ATG CCA, and antisense oligonucleotide: GCA CAG AGA CGG TGC TGC. t-PA sense oligonucleotide: GAC GAT ACT TAT GAC AAC GAC, and antisense oligonucleotide: TAT TAA ACA GAT GCT GTG AGG. The specificity of both PAI-1 and t-PA PCR products were confirmed by sequencing.
Transfection and luciferase assays
Cells were transiently transfected with the indicated constructs using the lipofection method (Lipofectamine, Life Technologies) and stimulated with 1 ng/ml of human recombinant TGF-b1 (R&D). Luciferase activities were quantified 24 h later by using a commercial kit (Promega). Values were normalized with respect of b-galactosidase activity as expressed by the SV40 b-galactosidase vector (Promega).
PAI-1 expression
Cells were incubated in methionine/cysteine-free minimal essential medium containing 50 mCi/ml of 35 S-methionine/ 35 Scysteine (Trans-label, NEN, 1100 Ci/mmol.) for 6 h at 37ЊC in the presence of TGF-b1 (1 ng/ml). Cells were removed by washing three times in a solution containing: 10 mM Tris-HCl (pH 8.0), 0.5% sodium deoxycholate with 1 mM phenylmethylsulfonyl fluoride. Cell matrix proteins were extracted and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed in the presence of dithiothreitol (DTT) and b-mercaptoethanol.
Immunoprecipitation
Metabolically labeled cells were solubilized in 1 ml of lytic buffer in the presence of protease inhibitors at 4ЊC for 30 min. By using specific antibodies, immunoprecipitations were performed from the supernatant of the lysis solution for 2 h at 4ЊC and followed by adsorption to protein G-Sepharose (Pharmacia Biotech). Bound proteins were eluted in DTT and bmercaptoethanol containing a loading sample buffer. Then an SDS-PAGE was performed.
Growth inhibition assay
After 20 h of treatment in the presence of 1 ng/ml of TGF-b1 in serum free medium, cells were labeled with 0.5 mCi/ml of 3 H-thymidine (specific activity 2200 Ci/mmol, NEN) for an additional 4 h. Cells were precipitated and washed three times in 5% trichloroacetic acid before extraction at 4ЊC in 0.1 N NaOH. The extracts were counted in a beta counter.
RESULTS

TGF-b1 selectively protects neurons against NMDAinduced necrosis in mixed neuron/glia cultures
It has been reported that TGF-b1 can reduce neuronal death induced by experimental ischemia (23) . In these situations, death is thought to occur both by necrosis and apoptosis. To test whether TGF-b1 is able to reduce neuronal death in different types of injury, we determined the effects of this growth factor on murine cortical cell cultures exposed to stimuli that specifically induce either apoptosis or necrosis.
To induce apoptosis, we transferred cortical pure neuronal cultures after 7 days in vitro (DIV 7) to a serum-deficient medium (24) , which provoked the death of approximately 50% of neurons over 24 h. This paradigm evidenced three features typical of apoptosis: 1) the neurons exhibited a gradual shrinkage of the cell body; 2) death was almost completely obviated by the addition of cycloheximide, a protein synthesis inhibitor; and 3) death was accompanied by the appearance of DNA fragmentation (data not shown). Addition of TGF-b1 to the bathing medium (at 1 ng/ml) failed to modify the progression and extent of neuronal degeneration.
We also induced neuronal apoptosis by exposing mixed neuron-glia cultures (DIV 14) to staurosporine, a nonspecific protein kinase inhibitor, which caused a neuronal degeneration evolving over 24 h (25) . Whereas cycloheximide totally blocked neuronal death, the addition of TGF-b1 (at 1 ng/ml) was without effect (Fig. 1A) .
Our next step was to determine the influence of TGF-b1 on necrosis, a process morphologically distinct from apoptosis and characterized by a prominent and early cell swelling. To induce necrosis, we used the following glutamatergic agonists: NMDA, AMPA, and kainate (26) . The exposure of mixed cortical neuron-glia cultures or pure cortical neuronal cultures (DIV 14) to these agonists produced acute swelling of neuronal bodies, followed 24 h later by widespread neuronal degeneration; the glia remained intact. Coincubation with increasing concentrations of TGF-b1 reduced neuronal death only in the instance of NMDA-induced necrosis in mixed neuron-glia cultures (Fig. 1B, C) . In contrast, TGFb1 failed to produce any neuroprotective effect in pure cortical cultures of neurons (Fig. 1D) .
Expression of TGF-b dominant negative receptor in astrocytes abolished TGF-b1 neuroprotective effect against NMDA-induced necrosis
We demonstrate here that TGF-b1 exerts its beneficial effects against excitotoxic necrosis only in mixed cortical neuron-glia cultures, results that would suggest an obligatory involvement of glia in the mechanisms responsible for the neuroprotective effect of TGF-b1 in the necrotic-type of cell death.
To test the hypothesis as to whether glia truly mediate this neuroprotective effect, we attempted to prevent the TGF-b1 response of astrocytes in mixed neuron-glia cultures. By using lipofection, we transfected the mixed neuron-glia cultures with b-galactosidase cDNA: these experiments revealed that only astrocytes expressed b-galactosidase ( Fig. 2A) . We estimated, by cell counting, that approximately 70% of the astrocytes were transfected. In mixed cortical cultures subjected to transfection, LDH levels were not modified (up to 48 h), which demon-/ 383c de08 Mp 1686 Tuesday Oct 20 11:08 PM LP-FASEB de08 , nÅ12) , with or without TGF-b1 (at 1 ng/ml) or with cycloheximide (CHX) at 1 mg/ml. TGF-b1 treatment is indicated by shaded columns. Significant differences from SD or STP by one-way ANOVA, followed by Student-Newman-Keuls test for multiple comparisons (Põ0.05). B) Cell death (%) estimated by LDH release (mean {SEM, nÅ12) in mixed cultures either under normal conditions or after a 24 h exposure to 10 mM AMPA or 50 mM of kainate (with 10 mM (5R,10S)-(/)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten: MK-801 added to block secondary NMDA receptors activation) with or without TGF-b1 at 1 ng/ml. C) Cell death (%) estimated by LDH release (mean {SEM, nÅ16) in mixed cultures of cortical neurons and astrocytes was studied under normal conditions or after a 24 h exposure to 12.5 mM NMDA without or with the indicated concentrations of TGF-b1. D) Bars show percent of cell death estimated by LDH release (mean {SEM, nÅ12) in pure cultures of neurons after 24 h exposure to 12.5 mM NMDA with the indicated concentrations of TGF-b1. #* Significantly different from NMDA alone or TGF-b1 alone respectively by oneway ANOVA followed by Student-Newman-Keuls test for multiple comparisons (Põ0.05).
strates that the procedure did not affect neuronal survival (data not shown). Then we selectively transfected astrocytes contained in mixed neuron-glia cultures with cDNA encoding for a TGF-b dominant negative receptor (TbR-IIEI). This chimeric receptor was generated by fusion of the extracellular domain of TbR-II with the transmembrane and the intracellular domain of TbR-I, preventing TGF-b1 responses (27) . The expression of the transfected TbR-IIEI receptor was determined in glia cultures by metabolic labeling of the TGF-b receptors, followed by immunoprecipitation with antibodies raised against the TbR-II extracellular domain. Complexes formed of TbRI and both endogenous TbRII or transfected TbRIIEI were expressed by astrocytes 24 h after the transfection protocol (Fig.  2B) . As it was important to determine whether the TbR-IIEI dominant negative receptor was able to prevent the TGF-b1-induced biological response, we studied the inhibitory role of TGF-b1 on astrocytic proliferation (28) S-cysteine in the presence of TGF-b1 at 37ЊC. The cell lysate was immunoprecipitated with an antibody raised against the extracellular domain of TbR-II (27) and subjected to SDS-PAGE electrophoresis and autoradiography. C) Influence of TGF-b1 on astrocytes proliferation estimated by 3 H-thymidine incorporation. Astrocytes were or were not (NT) transiently transfected with the empty pCMV5 (cross-hatched bars) or the pCMV5 vector containing the TbR-IIEI cDNA (pIIEI) (shaded bars) (mean {SEM, nÅ8) * Significantly different from NT by one-way ANOVA followed by Student-Newman-Keuls test for multiple comparisons (Põ0.05). D) Cell death (%) estimated by LDH release (mean {SEM, nÅ12) in mixed cultures transiently transfected as above with the empty pCMV5 or the pCMV5 vector containing the TbR-IIEI cDNA after a 24 h exposure to 12.5 mM NMDA with or without TGF-b1 at 1 ng/ml. * Significantly different from NMDA alone, # significantly different from NMDA/TGF-b1 by one-way ANOVA followed by Student-NewmanKeuls test for multiple comparisons (Põ0.05).
(075%) the TGF-b1-induced inhibition of glial proliferation (Fig. 2C) . These data show that transfection of the cDNA encoding for TbR-IIEI rendered astrocytes less responsive to TGF-b1. When the mixed neuron-glia cultures, transfected with TbR-IIEI, were exposed to NMDA, the neuroprotective effect of TGF-b1 was abolished in sister cultures (Fig.  2D ). This result underlines the fact that TGF-b1 protects neurons against NMDA-induced cell death when, and only when, TGF-b1-responsive astrocytes are present in the mixed cortical cultures.
PAI-1 and t-PA expression pattern in astrocytes and neurons: modulation by TGF-b1
First, to quantify PAI-1 transcriptional activity that depends on TGF-b1, we developed a luciferase reporter gene driven by the PAI-1 promotor (PAI-luciferase). The luciferase activity directly reflects the PAI-1 transcriptional level. TGF-b1 enhanced luciferase activity up to 60% and cotransfection with the TbR-IIEI dominant negative receptor totally prevented this response (Fig. 3A) . Next, we studied the ). * Significantly different from control; # significantly different from PCMV5/TGF-b1 by one-way ANOVA followed by a Student-Newman-Keuls test for multiple comparisons (Põ0.05). B) PCR for both PAI-1 and t-PA transcripts. Total mRNA from TGF-b1-treated astrocytes or neurons cultured in serum free medium were harvested after either 3 or 24 h of treatment. C) Immunoprecipitation of PAI-1. Control (C) and TGF-b1-treated (T) astrocytes were metabolically labeled in the serum-free medium containing 35 S-methionine and 35 S-cysteine. SDS-PAGE electrophoresis and autoradiography were performed without or with a previous immunoprecipitation (IP) by an antibody raised against PAI-1 (American Diagnostica). D) Immunoprecipitation with PAI-1 and tPA antibodies of cell lysates from mixed cultures of neurons and astrocytes subjected to IP. SDS-PAGE electrophoresis was performed in the presence of dithiothreitol and b-mercaptoethanol and revealed by Coomassie blue staining. Both antibodies immunoprecipitate already formed t-PA/PAI-1 complexes.
cell type that expressed t-PA or PAI-1 in both glial cultures and pure cultures of cortical neurons. By using reverse transcriptase PCR (RT-PCR), we showed that t-PA mRNA was expressed in both neurons and glia whereas PAI-1 mRNA expression was restricted to glia (Fig. 3B) . Moreover, enhanced expression of PAI-1 mRNA after TGF-b1 treatment was characteristic of the astrocytes. Expression of the t-PA mRNA was not influenced by TGF-b1 treatment in neuronal and astrocytic cultures. Furthermore, the increased PAI-1 expression in astrocytes subsequent to treatment with TGF-b1 was visualized, at the protein level, by SDS-PAGE of extracellular matrix-associated protein. As shown in Fig. 3C, TGF-b1 induced the overexpression of a protein with an approximate molecular mass of 50 kDa specifically immunoprecipitated by an antibody raised against PAI-1. The light microscope distribution of the specific antibodies for the two proteins studied matched the distribution of t-PA and PAI-1 mRNAs (Fig. 4) . To study the possibility of an interaction between PAI-1 and t-PA, immunoprecipitation with antibodies raised against PAI-1 and t-PA was performed both in mixed and in pure neuronal cultures. SDS-PAGE electrophoresis revealed the presence of complexes formed from PAI-1 and t-PA in mixed cultures of neurons and astrocytes but not in pure cultures of neurons (Fig. 3D) . 3) an antibody raised against PAI-1 (100 mg/ml) or the TGF-b1 at 1 ng/ml (A3, 4). The results were compared to cultures subjected neither to NMDA nor the PAI-1 antibody (A1). Scale bars: 100 mm. *Significantly different from NMDA alone; #significantly different from NMDA/TGF-b1 by one-way ANOVA, followed by Student-Newman-Keuls test for multiple comparisons (Põ0.05).
Blockade of PAI-1 activity prevents TGF-b1-induced neuroprotection
To test whether the neuroprotective effect of TGFb1 against NMDA-mediated necrosis involved the overexpression of PAI-1 in astrocytes, NMDA-induced toxicity in mixed cultures of neurons and astrocytes was performed in the presence of an antibody raised against PAI-1 that neutralizes the t-PA binding capacity of PAI-1 (29, 30) . Although coincubation of cultures with 100 mg/ml of this antibody did not modify NMDA-induced cell death, this treatment abolished the neuroprotective effect of TGF-b1 (Fig. 5A, B) .
DISCUSSION
In this study we have investigated the influence of TGF-b1 against apoptotic and excitotoxic neuronal cell death, two different types of cell death thought to be involved in ischemia-induced neuronal injury. We demonstrate here that, in contrast to other growth factors (6), TGF-b1 fails to exert any beneficial effect against apoptotic injury. Accordingly, TGFb1 can be described as a nonconventional growth factor. These findings are in contradistinction to earlier reports by Henrich-Noack et al. (31) that suggested a neuroprotective effect of pretreatment TGF-b1 against staurausporine-induced apoptosis. These discrepancies can be explained by differences in the regimen of TGF-b1 treatment and in the nature of cell culture systems used in these two studies with respect to our present paradigm.
We also demonstrate that application of TGF-b1 reduces excitotoxicity in cortical cell cultures. These results are in accordance with prior observations by Prehn et al. (23) , which described a broad spectrum of neuroprotection induced by TGF-b1. In our study, the neuroprotective activity of TGF-b1 was limited to
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NMDA receptor-mediated neuronal cell death. AMPA-and kainate-induced cell death (associated with MK 801) were not affected by a coincubation with TGF-b1, which would indicate that activation of TGF-b receptors specifically modulates NMDA-induced cell death. Additional investigations are needed to determine the reason of this selective neuroprotective effect of TGF-b1 against NMDA-induced excitotoxicity. Even though several reports (23, 31) have described the neuroprotective potential of this cytokine against necrosis, the mechanism of this action remains unclear. We document here that this growth factor exerts its beneficial effects against excitotoxic necrosis only in mixed cortical cultures. This result underlines the fact that TGF-b1 protects neurons against NMDA-induced cell death when, and only when, TGF-b1-responsive astrocytes are present in the mixed cortical cultures. We confirmed and extended this observation by demonstrating that TGF-b1 fails to exert any neuroprotective activity against NMDA-mediated excitotoxicity in pure neuronal cultures (containing less than 5% of astrocytes). These results would infer an involvement of glia in the mechanisms responsible for the neuroprotective effect of TGF-b1 in necrosis. Moreover, our results clearly show that PAI-1, a serine protease inhibitor, expressed only in astrocytes and overexpressed after TGF-b1 treatment, mediates the neuroprotective effect of TGF-b1. These observations suggest the involvement of extracellular matrix components in growth factor-induced neurons/glia communication.
Increasing evidence suggests that members of the serine protease family, such as the tissue-type plasminogen activator (t-PA) or thrombin, may play a role in normal and diseased nervous system. Serine proteases increase in the neural parenchyma and cerebrospinal fluid after brain injury (17, 18) . Recent data have demonstrated that t-PA increases neuronal damage after focal cerebral ischemia (32) , suggesting that t-PA may promote neuronal injury through its plasminogen-activating activity. Thus, proteases may dramatically influence the outcomes of various neuropathological insults. An equilibrium between serine proteases and their specific inhibitors (serpins) exists in many tissues where these agents are involved in physiological processes associated with inflammation, connective tissue turnover; nonetheless, no clear involvement of serpins was evident in either physiological or pathological processes in the central nervous system. We have shown that PAI-1, a selective inhibitor of tPA exclusively expressed in astrocytes, is up-regulated by TGF-b1 treatment. By blocking the ability of PAI-1 to inhibit tPA, we abolished the neuroprotective activity of TGF-b1 against NMDA neurotoxicity. These results underline the potential neuroprotective effect that would be obtained by a modulation of the t-PA/PAI-1 axis.
Regardless of the underlying mechanisms of the involvement of t-PA in excitotoxic injury, our observations might caution against the indiscriminate application of t-PA for the treatment of hypoxic-ischemic injury in brain tissue. Even when net beneficial effects are observed, the possibility that the overall neuroprotection is limited by concomitant potentiation of excitotoxic necrosis should be explored in appropriate animal models.
